B cell-targeted therapies in Sjögren's syndrome
- PMID: 19671451
- DOI: 10.1016/j.autrev.2009.08.001
B cell-targeted therapies in Sjögren's syndrome
Abstract
Sjögren's syndrome (SS) or autoimmune epithelitis is characterized by focal lymphocytic infiltrates surrounding the tubular epithelium of exocrine glands and by overactivity of the B-cell population. Although T cells were long considered the main effectors in SS, recent findings indicating a key role for B cells have prompted studies of treatments designed to deplete the B-cell population. Among molecules that can be targeted to achieve B-cell depletion, CD20 and CD22 are surface antigens expressed specifically by B lymphocytes; and the cytokine B-cell-activating factor belonging to the TNF family (BAFF) is a TNF receptor ligand involved in B-cell differentiation, survival, and activation. The aim of this review is to discuss the clinical outcomes of SS patients treated with B-cell depletion.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
Emerging biotherapies for Sjögren's syndrome.Expert Opin Emerg Drugs. 2010 Jun;15(2):269-82. doi: 10.1517/14728211003702392. Expert Opin Emerg Drugs. 2010. PMID: 20384543 Review.
-
Therapeutic potential for B-cell modulation in Sjögren's syndrome.Rheum Dis Clin North Am. 2008 Nov;34(4):1025-33, x. doi: 10.1016/j.rdc.2008.08.014. Rheum Dis Clin North Am. 2008. PMID: 18984420 Review.
-
B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.J Autoimmun. 2012 Sep;39(3):161-7. doi: 10.1016/j.jaut.2012.05.014. Epub 2012 Jun 30. J Autoimmun. 2012. PMID: 22749831 Review.
-
Rituximab therapy in primary Sjögren's syndrome.Ann N Y Acad Sci. 2009 Sep;1173:701-5. doi: 10.1111/j.1749-6632.2009.04639.x. Ann N Y Acad Sci. 2009. PMID: 19758218
-
The future of B cell-targeted therapies in Sjögren's syndrome.Immunotherapy. 2013 Jun;5(6):639-46. doi: 10.2217/imt.13.49. Immunotherapy. 2013. PMID: 23725286 Review.
Cited by
-
B Cell in Autoimmune Diseases.Scientifica (Cairo). 2012;2012:215308. doi: 10.6064/2012/215308. Scientifica (Cairo). 2012. PMID: 23807906 Free PMC article.
-
Influence of sex hormones and genetic predisposition in Sjögren's syndrome: a new clue to the immunopathogenesis of dry eye disease.Exp Eye Res. 2012 Mar;96(1):88-97. doi: 10.1016/j.exer.2011.12.016. Epub 2011 Dec 28. Exp Eye Res. 2012. PMID: 22227485 Free PMC article.
-
APRIL and BAFF: novel biomarkers for central nervous system lymphoma.J Hematol Oncol. 2019 Oct 15;12(1):102. doi: 10.1186/s13045-019-0796-4. J Hematol Oncol. 2019. PMID: 31615554 Free PMC article.
-
Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now?BioDrugs. 2021 Nov;35(6):593-610. doi: 10.1007/s40259-021-00505-7. Epub 2021 Nov 3. BioDrugs. 2021. PMID: 34731460 Review.
-
Biologic therapy for refractory scleritis: a new treatment perspective.Int Ophthalmol. 2015 Dec;35(6):903-12. doi: 10.1007/s10792-015-0124-0. Epub 2015 Aug 29. Int Ophthalmol. 2015. PMID: 26319144 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical